Get the Stockscreener App
7.97
0.06%
-0.005
After Hours:
7.92
-0.05
-0.63%
Kyntra Bio Inc stock is traded at $7.97, with a volume of 9,682.
It is down -0.06% in the last 24 hours and up +12.73% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$7.975
Open:
$8.175
24h Volume:
9,682
Relative Volume:
0.44
Market Cap:
$32.27M
Revenue:
$7.44M
Net Income/Loss:
$-56.57M
P/E Ratio:
0.2902
EPS:
27.467
Net Cash Flow:
$-21.40M
1W Performance:
-6.78%
1M Performance:
+12.73%
6M Performance:
+11.94%
1Y Performance:
+0.00%
1-Day Range:
$7.92
$8.25
1-Week Range:
$7.03
$8.50
52-Week Range:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
7.97 | 32.27M | 7.44M | -56.57M | -21.40M | 27.47 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
Kyntra Bio (KYNB) CEO reports RSU tax withholding, not a stock sale - Stock Titan
Kyntra Bio (KYNB) CFO holds 4,355 shares after tax withholding - Stock Titan
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - Kalkine
KIN stock holds steady as Kyntra Bio prepares new earnings update - ad-hoc-news.de
Kyntra Bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
A drug company's CEO will present in New York Sept. 15. Kyntra Bio will webcast it. - Stock Titan
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
KYNB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction - Investing.com
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction By Investing.com - Investing.com South Africa
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet - TipRanks
KYNB Looks 65.5% Overvalued on GF Value™ - GuruFocus
Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment - marketscreener.com
Kyntra Bio Amends Revenue Interest Deal With NQ Project Phoebus, Cuts Cap to $65M, Pays $42.6M - TradingView
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - marketscreener.com
Kyntra Bio (KYNB) Edges Higher to $8.02, Up 0.25% as Stock Holds Between Key LevelsEMA Signal - dars.gov.et
Enterprise value to revenue forward of Kyntra Bio, Inc. – BX:KYNB - TradingView
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript - AOL.com
Kyntra Bio, Inc.Common Stock (Nasdaq:KYNB) Stock Quote - FinancialContent
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advanc - GuruFocus
Kyntra Bio, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-08-16 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackSector Neutral Pair - vinanet.vn
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc Q2 Net Income From Cont Ops US - moomoo.com
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - aol.com
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - Benzinga
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - Quiver Quantitative
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn - Stock Titan
Kyntra Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kyntra Bio Targets Late-2026 Milestones for Cancer and Anemia Drugs - Stock Titan
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
KYNB Q1 2026 Earnings: EPS Miss Deepens as Losses Exceed ExpectationsRevenue Estimate Trend - vinanet.vn
Kyntra Bio, Inc. expected to post a loss of $3.18 a shareEarnings Preview - TradingView
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on August 13 - 富途牛牛
KYNB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnGeographic Revenue Trends - vinanet.vn
KYNB Q2'26 Earnings: EPS estimate is (3.18) USD - TradingView
Kyntra Bio to Report Second Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
KYNB Q2'26 Earnings: revenue estimate is 2.09M USD - TradingView
Kyntra Bio Inc. (KYNB) Edges Lower by 0.88% to $6.73 as Shares Consolidate Between Key Support and ResistanceCommon Gap - vinanet.vn
Kyntra Bio Inc Stock (KYNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kyntra Bio Inc Stock (KYNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):